by Ethan Perlstein | Nov 4, 2017 | Start-ups, Uncategorized |
This week we announced a $7.4M equity financing. Endpoints News and STAT News covered the announcement and the Twitter angle. Here’s the backstory from the CEO’s vantage point. From the outside, this round appears to be our Series A. But it’s technically our...
by Nina DiPrimio | Jul 5, 2016 | Uncategorized |
I have been anxiously awaiting this moment, the time in which I can write a blog post on our pilot study with Vium, formerly Mousera. Perlstein Lab had an opportunity to work with Vium starting about one year prior to their out-of-stealth launch, and I am itching to...
by Nina DiPrimio | May 17, 2016 | Uncategorized |
It has been a while since you have heard from me. We are deep in post screen characterization of our NPC hits so I thought I would take a step back to the beginning to discuss NPC disease biology. We focused a bit on the cholesterol and lipid metabolism aspects of...
by Tamy Portillo Rodriguez | Mar 31, 2016 | Blogposts, Uncategorized |
Dimethly Sulfoxide, commonly known as DMSO, is a small molecule composed of two methyl groups attached to a Sulfur with an Oxygen (C2H6OS). It was the production of cheaper paper that led to the discovery of this colorless liquid in the 19th Century, but it was its...
by Sangeetha Iyer | Jan 20, 2016 | Uncategorized |
Or in other words, bypass pathways. Happy 2016 everyone! Here at PLab things have gotten off to a great start. You’ll keep hearing updates from other members of our team right here! In the meantime, I figured we’d kick off the new year with a broad...
by Nina DiPrimio | Dec 14, 2015 | Uncategorized |
To continue on the theme of understanding your compound of interest’s mechanism of action, let’s discuss target identification (ID). You have just completed your screen and found a hit, but now you want to learn more about why it is a hit. As mentioned before,...
